QR код

Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study

Abstract Daratumumab is approved for patients with multiple myeloma (MM) and high-risk smoldering MM (HR-SMM). However, HR-SMM is often as genomically complex as MM, suggesting it may be too advanced for single-agent intervention. We report on a Phase II trial of single-agent daratumumab in patients...

Повний опис

Збережено в:
Автори: Omar Nadeem, Michelle P. Aranha, Robert A. Redd, Michael Koontz, Jeffrey V. Matous, Andrew J. Yee, Jeffrey A. Zonder, Andrew Kin, Sophie Magidson, Elizabeth D. Lightbody, Ting Wu, Floris Chabrun, Jean-Baptiste Alberge, Ankit K. Dutta, Jacqueline Perry, Ashlee Sturtevant, Mahshid Rahmat, Junko Tsuji, Christine Davie, Caroline Ricciardi, Frances Arters, Marjorie Marto, Amy Bergeron, Jacalyn Rosenblatt, Elizabeth K. O’Donnell, Tarek H. Mouhieddine, Lorena Pantano, Jacob P. Laubach, Paul G. Richardson, Gad Getz, Lorenzo Trippa, Romanos Sklavenitis-Pistofidis, Irene M. Ghobrial
Формат: Artigo
Мова:Inglês
Опубліковано: Nature Portfolio 2026-04-01
Серія:Nature Communications
Онлайн доступ:https://doi.org/10.1038/s41467-026-71483-z
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси